Osstem Implant stake in Hans Biomedical rises to 12.48% following conversion price adjustment

stake_5pct · spotted Sep 2, 2026, 5:22 PM KST

• Osstem Implant (오스템임플란트), reported as major shareholder, now holds 1,415,354 shares representing 12.48% of Hans Biomedical
• Previous IRDS (convertible instrument) position was 58,373 shares or 0.44% of total
• Stake increase triggered by conversion price adjustment and related-party on-market purchases/sales

Conversion of IRDS and adjustment mechanics have moved Osstem Implant above the 5% disclosure threshold into material shareholder territory, potentially affecting control dynamics and future capital allocation decisions at Hans Biomedical.

AI-generated summaries of public DART filings. May contain errors — always verify against the original (linked). Not investment advice.